Metabolomics and Type 2 Diabetes: Translating Basic Research into Clinical Application
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes (T2D) and its comorbidities have reached epidemic proportions, with more than half a billion cases expected by 2030. Metabolomics is a fairly new approach for studying metabolic changes connected to disease development and progression and for finding predictive biomarkers to enable early interventions, which are most effective against T2D and its comorbidities. In metabolomics, the abundance of a comprehensive set of small biomolecules (metabolites) is measured, thus giving insight into disease-related metabolic alterations. This review shall give an overview of basic metabolomics methods and will highlight current metabolomics research successes in the prediction and diagnosis of T2D. We summarized key metabolites changing in response to T2D. Despite large variations in predictive biomarkers, many studies have replicated elevated plasma levels of branched-chain amino acids and their derivatives, aromatic amino acids and α-hydroxybutyrate ahead of T2D manifestation. In contrast, glycine levels and lysophosphatidylcholine C18:2 are depressed in both predictive studies and with overt disease. The use of metabolomics for predicting T2D comorbidities is gaining momentum, as are our approaches for translating basic metabolomics research into clinical applications. As a result, metabolomics has the potential to enable informed decision-making in the realm of personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 1×
“The net reclassification improvement (NRI), an alternative measure for prediction power [61] for these models, increased from 0.”
MethodThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.002 · Cited by 3,165
Metabolite profiles and the risk of developing diabetes
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2307 · Cited by 3,143 · cited 2×
“7 years ahead of clinical manifestation [35, 36, 40], in PD [39, 43–47] and in overt T2D [35, 37, 43, 46, 49, 50].”
BackgroundMethodKoves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens, R., Dyck, J. R. B., Newgard, C. B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.013 · Cited by 1,990
Floegel, A., Stefan, N., Yu, Z., Mühlenbruch, K., Drogan, D., Joost, H.-G., Fritsche, A., Häring, H.-U., Hrabě de Angelis, M., Peters, A., et al. (2013) · Diabetes · doi:10.2337/db12-0495 · Cited by 988 · cited 9×
“Glycine, on the other hand, was found to be reduced 7 years before T2D [36, 37], as well as in PD [37, 38, 47] and in manifest T2D [37].”
BackgroundInfluentialMorino, K., Petersen, K. F., & Shulman, G. I. (2006) · Diabetes · doi:10.2337/db06-s002 · Cited by 853 · cited 1×
“While some studies suggest that PD develops secondary to diminished fatty acid oxidation by cytosolic lipid accumulation, thereby impairing insulin signaling [56], other studies suggest PD to be characterized by excessive fatty acid oxidation, metabolic inflexibility, and coincident depletion of organic acid intermedi…”
Background
Cited by
Thingholm, L. B., Rühlemann, M. C., Koch, M., Fuqua, B., Laucke, G., Boehm, R., Bang, C., Franzosa, E. A., Hübenthal, M., Rahnavard, A., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.07.004 · Cited by 451
Inflammation, vitamin B6 and related pathways
Ueland, P. M., McCann, A., Midttun, Ø., & Ulvik, A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.08.001 · Cited by 382
Wang, R., Li, B., Lam, S. M., & Shui, G. (2020) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.009 · Cited by 330
Diabetes and branched‐chain amino acids: What is the link?: 糖尿病与支链氨基酸:有什么关联吗?
Bloomgarden, Z. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12645 · Cited by 229
Zhao, X., Han, Q., Liu, Y., Sun, C., Gang, X., & Wang, G. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2794591 · Cited by 174
Metadata
- Authors
- Klein, M. S., & Shearer, J.
- Venue
- Journal of Diabetes Research
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-10
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- OpenAlex
- W2169845921
- Cited by
- 141
- References
- 17
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolomics and Type 2 Diabetes: Translating Basic Research into Clinical Application. https://app.cochat.ai/papers/10.1155/2016/3898502
- The paper
- Klein, M. S., & Shearer, J. (2016). Metabolomics and Type 2 Diabetes: Translating Basic Research into Clinical Application. Journal of Diabetes Research. https://doi.org/10.1155/2016/3898502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.